CONMED Corporation (NASDAQ:CNMD) announced its quarterly earnings data on Thursday. The medical technology company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01, Bloomberg Earnings reports. The company had revenue of $190.10 million during the quarter, compared to the consensus estimate of $187.13 million. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. CONMED Corporation’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.41 EPS. CONMED Corporation updated its FY17 guidance to $1.85-1.90 EPS.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 5th. Shareholders of record on Friday, September 15th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, September 14th. This represents a $0.80 dividend on an annualized basis and a yield of 1.53%. CONMED Corporation’s payout ratio is currently 142.86%.

In other CONMED Corporation news, Director Jo Ann Golden sold 3,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the director now directly owns 19,782 shares in the company, valued at $989,100. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.62% of the company’s stock.

CNMD has been the subject of a number of analyst reports. BidaskClub downgraded shares of CONMED Corporation from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 20th. Needham & Company LLC restated a “buy” rating and set a $57.00 price objective on shares of CONMED Corporation in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of CONMED Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday. KeyCorp restated a “hold” rating on shares of CONMED Corporation in a research report on Friday, August 25th. Finally, TheStreet upgraded shares of CONMED Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $52.50.

COPYRIGHT VIOLATION NOTICE: “CONMED Corporation (CNMD) Announces Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/02/conmed-corporation-cnmd-announces-earnings-results.html.

CONMED Corporation Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Earnings History for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.